Expert care for cancers of the urinary system and male reproductive organs — kidney, bladder, prostate, and testicular cancers — with minimally invasive robotic surgery, precision-targeted therapy, and immunotherapy delivered through a real-time MDT model.
A multidisciplinary urologic oncology center integrating urologic surgery, medical oncology, radiation oncology, pathology, imaging, and interventional radiology into a single coordinated team.
The Urologic Oncology Center at Beijing Arion Cancer Hospital is dedicated to the full-spectrum management of cancers affecting the kidneys, bladder, prostate, and testes. Our philosophy is grounded in the principle of organ preservation and functional recovery — aiming to eradicate cancer while maintaining urinary function, sexual health, and overall quality of life.
Our center brings together specialists from urologic surgery, medical oncology, radiation oncology, pathology, diagnostic imaging, and interventional radiology — forming a dedicated MDT core team that follows each patient from initial diagnosis through treatment and long-term surveillance. This real-time, full-term MDT model means treatment strategies are developed collaboratively, not in isolation, and are continuously adjusted based on treatment response and evolving clinical evidence.
We manage the entire spectrum of urologic malignancies — from localized early-stage tumors amenable to minimally invasive surgery, to locally advanced disease requiring multimodal therapy, to metastatic cancer where systemic therapy and palliative interventions are the mainstay. With access to the latest robotic surgical platforms, advanced radiation techniques, and cutting-edge systemic therapies, our center delivers care aligned with international guidelines, including NCCN and EAU standards.
Cancer eradication + organ preservation + functional recovery
Every urologic cancer patient receives a dedicated multidisciplinary team from the first consultation, ensuring real-time collaboration across all relevant specialties throughout the entire treatment journey.
Our MDT team jointly reviews high-resolution imaging (multiparametric MRI, CT urography, PSMA-PET for prostate cancer), histopathology with molecular markers, and genomic profiling to establish precise diagnosis and staging. Urologic surgeons, radiologists, pathologists, and medical oncologists collaborate in a single consensus discussion, eliminating the delays and fragmentation inherent in traditional sequential referral models.
Treatment plans are individually tailored based on cancer type, stage, grade, molecular profile, and each patient's priorities regarding organ preservation and functional outcomes. The MDT team evaluates surgical options (open, laparoscopic, robotic-assisted), radiation therapy (IMRT, SBRT), systemic therapy (chemotherapy, targeted therapy, immunotherapy), and active surveillance protocols — all sequenced for maximum efficacy and minimum morbidity.
Unlike conventional care where treatment plans are set at the start and rarely revised, our MDT team meets regularly to review each patient's progress. If imaging shows an unexpected response to neoadjuvant therapy, or if pathology reveals features warranting a different approach, the plan is adjusted in real time with the entire team aligned. This dynamic model is especially valuable in urologic cancers where treatment sequencing can significantly impact both oncologic and functional outcomes.
A comprehensive range of evidence-based urologic cancer treatments, individually customized and MDT-coordinated to maximize both oncologic control and quality of life.
Our center provides specialized care for the full spectrum of urologic malignancies.
Renal cell carcinoma management including partial nephrectomy, radical nephrectomy, ablative therapies, and systemic treatment with tyrosine kinase inhibitors, mTOR inhibitors, and immunotherapy combinations for advanced disease.
Transurethral resection, intravesical therapy (BCG, chemotherapy), radical cystectomy with urinary diversion, bladder-preserving trimodal therapy, and systemic treatment including chemotherapy and checkpoint immunotherapy.
Active surveillance protocols, robotic-assisted radical prostatectomy, external beam radiation (IMRT/SBRT), brachytherapy, androgen deprivation therapy, novel hormonal agents, and radiopharmaceutical therapy for advanced disease.
Radical orchiectomy, retroperitoneal lymph node dissection, surveillance protocols, and curative chemotherapy regimens. Our team is experienced in managing both seminomatous and non-seminomatous germ cell tumors across all stages.
Our treatment armamentarium spans surgery, radiation, systemic therapy, and interventional approaches.
Laparoscopic and robotic-assisted procedures including partial and radical nephrectomy, radical prostatectomy, and radical cystectomy. These approaches offer smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery while maintaining excellent oncologic outcomes. Robotic platforms provide enhanced 3D visualization and wristed instrumentation for precise dissection in confined pelvic and retroperitoneal spaces.
Precision systemic therapy directed at specific molecular drivers of urologic cancers. For renal cell carcinoma, this includes tyrosine kinase inhibitors (sunitinib, pazopanib, cabozantinib), mTOR inhibitors, and HIF-2a inhibitors. For prostate cancer, novel hormonal agents (abiraterone, enzalutamide, apalutamide) and PARP inhibitors for BRCA-mutated disease. Each treatment is selected based on tumor genomics and individual patient factors.
Immune checkpoint inhibitors have transformed the treatment landscape for urologic cancers. Our center offers PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, avelumab) and CTLA-4 inhibitors (ipilimumab) for renal cell carcinoma, urothelial carcinoma, and selected prostate cancers. Combination immunotherapy regimens and immunotherapy-tyrosine kinase inhibitor combinations are utilized based on the latest clinical evidence and guideline recommendations.
Advanced radiation techniques including IMRT (intensity-modulated radiation therapy), IGRT (image-guided radiation therapy), and SBRT (stereotactic body radiation therapy) for prostate cancer, bladder-preserving protocols, and oligometastatic disease. Brachytherapy (low-dose-rate seed implantation or high-dose-rate temporary implants) is available for appropriately selected prostate cancer patients.
Cisplatin-based combination chemotherapy remains a cornerstone for muscle-invasive bladder cancer (neoadjuvant and adjuvant), metastatic urothelial carcinoma, and testicular cancer — where curative chemotherapy regimens achieve excellent outcomes. Our medical oncology team manages chemotherapy delivery with proactive supportive care to minimize side effects while maintaining dose intensity.
For selected patients with small renal masses or oligometastatic disease, image-guided ablative techniques including radiofrequency ablation (RFA), microwave ablation, and cryoablation offer effective tumor control with minimal morbidity. These procedures are performed in collaboration with our interventional radiology team as part of the comprehensive treatment algorithm.
Our Urologic Oncology Center is anchored by expert urologic surgeons and oncologists from China's leading academic medical centers, bringing decades of specialized experience to the MDT team.
A distinguished urologic surgeon from Peking University First Hospital, one of China's premier urology centers. Dr. Xi brings decades of experience in the surgical management of urologic malignancies, with particular expertise in complex oncologic procedures involving the kidneys, bladder, prostate, and retroperitoneum. He is skilled in both open and minimally invasive surgical approaches, and contributes critical surgical perspective to the MDT team's treatment planning for every urologic cancer patient. His deep understanding of pelvic and retroperitoneal anatomy enables organ-preserving surgical strategies that prioritize both cancer control and functional recovery.
Our unique advantages make us a leading destination for international patients seeking world-class urologic cancer care in China.
Our clinical pathways and quality metrics are aligned with UPMC (University of Pittsburgh Medical Center), bringing American cancer care standards to Beijing. For complex urologic cases, remote consultation with UPMC urologic oncology specialists is available through our partnership.
Our center is equipped with advanced robotic surgical platforms that enable precise, minimally invasive procedures for prostate, kidney, and bladder cancers. Robotic-assisted surgery offers superior visualization, enhanced dexterity, and improved preservation of surrounding nerves and structures critical for urinary continence and sexual function.
Every treatment decision in our MDT model considers not only cancer eradication but also the preservation of urinary, sexual, and renal function. Our urologic surgeons, radiation oncologists, and medical oncologists collaborate to select the treatment strategy that achieves the best balance of cancer control and quality of life for each individual patient.
Every international patient is assigned a dedicated Case Manager who coordinates all appointments, facilitates communication with the MDT team, arranges interpretation services, and provides logistical support from initial contact through treatment completion and follow-up. Language barriers and navigation challenges are systematically addressed.
Urologic cancer survivorship requires long-term monitoring for recurrence, management of treatment-related effects on urinary and sexual function, and surveillance for second primary malignancies. Our survivorship program provides structured follow-up protocols, rehabilitation services, and psychosocial support for patients who have completed active treatment.
Through our academic partnerships and commitment to evidence-based practice, our center stays at the forefront of urologic oncology advances. Patients benefit from access to the latest systemic therapies, surgical techniques, and radiation technologies as they become available, supported by treatment protocols aligned with international guidelines.